Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 291 for your search:
Start Over
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: ABI-007-NSCL-005, NCI-2014-02488, NCT02151149
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CO-1686-022 (TIGER-1), NCI-2014-02300, NCT02186301
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 140503, NCI-2009-00447, CDR0000555324, ECOG-40503, NCT00499330
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2303, NCI-2014-00520, 2012-005637-36, NCT01828112
Comparing Photon Therapy To Proton Therapy To Treat Patients with Lung Cancer
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: RTOG-1308, NCI-2013-01850, NCT01993810
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-NSCL-003, NCI-2014-01528, 2014-003804-66, NCT02027428
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4512, NCI-2014-01507, NCT02201992
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BR31, NCI-2015-01967, ACTRN12615000323527, IFCT1401, NCT02273375
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, U1111-1160-2242, NCT02296125
Start Over